| Abstract |
The different studies described in this thesis focus on better understanding of individualized diagnostics, response evaluation and multi modality treatments in non-small cell lung cancer (NSCLC) patients. In part I the novel biological agents erlotinib and cetuximab are evaluated in a new, multimodality treatment setting in resectable and locally advanced patients, respectively. Part II focuses on improving radiotherapy by mediastinal lymph node position variability analysis and image guided corrections, in locally advanced NSCLC.
|
